

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., DR. REDDY'S LABORATORIES,
INC. DR. REDDY'S LABORATORIES, LTD., SUN PHARMACEUTICAL
INDUSTRIES LTD., AND SUN PHARMACEUTICAL INDUSTRIES, INC.
Petitioner

v.

NOVO NORDISK A/S,
Patent Owner

Case IPR2023-00724¹
Patent 10,335,462

PATENT OWNER'S REQUEST FOR ORAL HEARING

¹ IPR2024-00009 (Dr. Reddy's Laboratories) and IPR2024-00107 (Sun
Pharmaceutical Industries) have been joined with this proceeding.

Pursuant to 37 C.F.R. §42.70(a), requiring a separate paper requesting oral hearing and specifying issues to be argued, Patent Owner 10x Novo Nordisk A/S. (“Novo”) submits this Request for Oral Hearing on the instituted grounds of unpatentability for claims 1-10 of U.S. Patent No. 10,335,462 under 35 U.S.C. §§102 and 103 and associated issues, including, without limitation, any raised in submissions to the Board (including any future submissions).

Patent Owner requests 90 minutes² of argument per side. Patent Owner understands the Board ordinarily provides an hour of argument per side in accordance with the Board’s guidance in the Consolidated Trial Practice Guide. Here, Patent Owner believes more time is appropriate due to the complexity of the case, including the arguments relating to swearing behind certain of Petitioner’s asserted references and objective indicia of non-obviousness, and the unusually large number of declarants and evidentiary exhibits. Patent Owner further requests that, in the event Petitioner reserves time for rebuttal, that Patent Owner be permitted to reserve time for a brief sur-rebuttal. Patent Owner further requests the services of a court reporter to transcribe the proceeding.

Patent Owner respectfully requests that the oral hearing be held remotely by videoconference. Pap.11, 6. In the event the Board instead holds the hearing in

² Patent Owner reached out to Petitioner regarding the length of the hearing but did not reach agreement.

person, Patent Owner expects that there will be no more than twelve individuals present on behalf of Patent Owner. Patent Owner further respectfully requests that its attorneys be permitted to use computers at any in-person hearing to avoid the need for parties to bring paper copies of the record into the hearing room. If in person, Patent Owner further requests the use of audio-visual equipment to display demonstratives or exhibits at the oral hearing.

Respectfully submitted,

Dated: July 12, 2024

By: /Megan Raymond/

J. Steven Baughman (Reg. No. 47,414)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5832
steve.baughman@groombridgewu.com

Megan Raymond (Reg. No. 72,997)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5878
megan.raymond@groombridgewu.com

Attorneys for Patent Owner Novo Nordisk A/S

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of PATENT OWNER'S REQUEST FOR ORAL HEARING has been served in its entirety by causing the aforementioned document to be electronically mailed to the following attorneys of record for Petitioners listed below:

Petitioner's Counsel of Record:

Lead Counsel for Mylan Pharmaceuticals, Inc.:	Brandon M. White Reg. No. 52,354 White-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Suite 800 Washington, DC 20005 Telephone: (202) 654-6200 By Electronic Mail
Backup Counsel:	Emily J. Greb Reg. No. 68,244 Greb-ptab@perkinscoie.com Perkins Coie LLP 33 East Main Street Madison, WI 53703 Telephone: (608) 663-7460 Courtney Prochnow, PhD Reg. No. 67,639 Prochnow-ptab@perkinscoie.com Perkins Coie LLP 633 W. 5th St., Ste 5850 Los Angeles, CA 90071 Telephone: (310) 788-9900 Christopher D. Jones

	Reg. No. 76,472 Jones-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Suite 800 Washington, DC 20005 Telephone: (202) 654-6200 Jonathan I. Tietz, PhD Reg. No. 76,753 Tietz-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Suite 800 Washington, DC 20005 Telephone: (202) 654-6200 Matthew A. Lembo Reg. No. 75,633 Lembo-ptab@perkinscoie.com Perkins Coie LLP 1155 Avenue of the Americas Floor 22 New York, NY 10036 Telephone: (212) 262-6900 Shannon M Bloodworth (Admitted <i>pro hac vice</i>) SBloodworth@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Suite 800 Washington, DC 20005 Telephone: (212) 654-6200 David L. Anstaett (Admitted <i>pro hac vice</i>) DAnstaett@perkinscoie.com Perkins Coie LLP 33 East Main Street
--	--

Madison, WI 53703
Telephone: (608) 663-7460

Bryan D. Beel
(Admitted *pro hac vice*)
BBeel@perkinscoie.com
Perkins Coie LLP
1120 NW Couch St.
10th Floor
Portland, OR 97209
Telephone: (503) 727-2000

Nathan Kelley
Reg. No. 45,295
Kelly_nathan-ptab@perkinscoie.com
Perkins Coie LLP
700 13th Street, NW
Suite 800
Washington, DC 20005
Telephone: (202) 654-6200

Rodney Swartz
Reg. No. 73,343
RSwartz@perkinscoie.com
Perkins Coie LLP
1120 NW Couch St.
10th Floor
Portland, OR 97209
Telephone: (503) 727-2000

Semaglutide-Ozempic@perkinscoie.com

By Electronic Mail

Lead Counsel for Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories. Ltd.:	Jovial Wong Reg. No. 60,115 Winston & Strawn LLP 1901 L Street NW Washington, DC 20036 Telephone: (202) 282-5867 jwong@winston.com By Electronic Mail
Backup Counsel:	Scott Border Reg. No. 77,744 Winston & Strawn LLP 1901 L Street NW Washington, DC 20036 Telephone: (202) 285-5054 sborder@winston.com Sharon Lin McIntosh (<i>pro hac vice</i> to be submitted) Winston & Strawn LLP 1901 L Street NW Washington, DC 20036 Telephone: (202) 285-5756 slin@winston.com By Electronic Mail

Lead Counsel for Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc.:	Brian Sodikoff KATTEN MUNCHIN ROSENMAN LLP 525 West Monroe Street Chicago, IL 60661 P: (312) 902-5200 brian.sodikoff@katten.com By Electronic Mail
Backup Counsel:	Christopher B. Ferenc KATTEN MUNCHIN ROSENMAN LLP 1919 Pennsylvania Ave., N.W. Suite 800 Washington, DC 20006 P: (202) 625-3500 christopher.ferenc@katten.com By Electronic Mail

Dated: July 12, 2024

Respectfully submitted,

By: /Sayem Osman/
Sayem Osman